Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AMI-1 | ? unclear | Mechanistic | DGIdb | |
| DIBEKACIN | ? unclear | Mechanistic | DGIdb | |
| CARBONYL CYANIDE M-CHLOROPHENYLHYDRAZONE | ? unclear | Mechanistic | DGIdb | |
| TRIPARANOL | ? unclear | Mechanistic | DGIdb | |
| DODINE | ? unclear | Mechanistic | DGIdb | |
| TANNIC ACID | ? unclear | Mechanistic | DGIdb | |
| DEFLAZACORT | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1235854 | ? unclear | Mechanistic | DGIdb | |
| ERGONOVINE | ? unclear | Mechanistic | DGIdb | |
| AMPEROZIDE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ATROPINE METHYLBROMIDE | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| BERBERINE CHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NITRALIN | ? unclear | Mechanistic | DGIdb | |
| DEVAZEPIDE | ? unclear | Mechanistic | DGIdb | |
| MOCLOBEMIDE | ? unclear | Mechanistic | DGIdb | |
| GLPG0492 | ~ modulates | Mechanistic | DGIdb | |
| DEUTENZALUTAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PRUXELUTAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| HEPTANE | ? unclear | Mechanistic | DGIdb | |
| THONZONIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| FENHEXAMID | ? unclear | Mechanistic | DGIdb | |
| LEMILDIPINE | ? unclear | Mechanistic | DGIdb | |
| (R)-BICALUTAMIDE | ? unclear | Mechanistic | DGIdb | |
| MORICIZINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| METIPRANOLOL | ? unclear | Mechanistic | DGIdb | |
| FLUROCHLORIDONE | ? unclear | Mechanistic | DGIdb | |
| PYRIDOSTIGMINE BROMIDE | ? unclear | Mechanistic | DGIdb | |
| FLUTAMIDE | ↓ inhibits | Mechanistic | 154.0 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL224318 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL423081 | ? unclear | Mechanistic | DGIdb | |
| PREDNISOLONE | ? unclear | Mechanistic | 2760.0 nM (Ki) | DGIdb |
| ORBIFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | 8.5 nM (Ki) | DGIdb |
| FLUDIOXONIL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1784521 | ? unclear | Mechanistic | DGIdb | |
| FLUMETHASONE | ? unclear | Mechanistic | DGIdb | |
| SERTRALINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MELOXICAM | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL44011 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 994 agents ranked by evidence tier.
IGF1
IL1B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| NICARDIPINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CANAKINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TT-301 | ? unclear | Mechanistic | DGIdb | |
| LITHIUM CATION | ? unclear | Mechanistic | DGIdb | |
| THYROGLOBULIN | ? unclear | Mechanistic | DGIdb | |
| LUTIKIZUMAB | ? unclear | Mechanistic | DGIdb | |
| CEFACLOR ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CLODRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| CELASTROL | ? unclear | Mechanistic | DGIdb | |
| ACITRETIN | ? unclear | Mechanistic | DGIdb | |
| RESVERATROL | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| PENTAMIDINE | ? unclear | Mechanistic | DGIdb | |
| DRUGSATFDA.NDA:008378 | ? unclear | Mechanistic | DGIdb | |
| RILONACEPT | ↓ inhibits | Mechanistic | DGIdb | |
| USTEKINUMAB | ? unclear | Mechanistic | DGIdb | |
| BECLOMETHASONE DIPROPIONATE | ? unclear | Mechanistic | DGIdb | |
| DIACETYLRHEIN | ? unclear | Mechanistic | DGIdb | |
| RISEDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTISONE BUTYRATE | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA EXTRACT | ? unclear | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| ETIDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| OFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| CDP-484 | ↓ inhibits | Mechanistic | DGIdb | |
| ERYTHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC MELATONIN | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| TETRADECANOYLPHORBOL ACETATE | ? unclear | Mechanistic | DGIdb | |
| HYDROQUINONE | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| NIMUSTINE | ? unclear | Mechanistic | DGIdb | |
| POLYVALENT VACCINE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 216 agents ranked by evidence tier.
NLRP3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| MCC950 | ↓ inhibits | Mechanistic | DGIdb | |
| TRICLOCARBAN | ? unclear | Mechanistic | 1490.0 nM (IC50) | DGIdb |
| CY-09 | ↓ inhibits | Mechanistic | DGIdb | |
| EMLENOFLAST | ↓ inhibits | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601543 | ? unclear | Mechanistic | DGIdb | |
| DAPANSUTRILE | ↓ inhibits | Mechanistic | DGIdb | |
| ORIDONIN DERIVATIVE 32 [PMID: 38751194] | ↓ inhibits | Mechanistic | DGIdb | |
| NDT-19795 | ↓ inhibits | Mechanistic | DGIdb | |
| NT-0796 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 15Z [PMID: 38029358] | ↓ inhibits | Mechanistic | DGIdb | |
| ANAKINRA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602526 | ? unclear | Mechanistic | DGIdb | |
| SELNOFLAST | ↓ inhibits | Mechanistic | DGIdb | |
| 4'-METHOXYFLAVONE | ? unclear | Mechanistic | 31000.0 nM (IC50) | DGIdb |
| CLIOXANIDE | ? unclear | Mechanistic | 1610.0 nM (IC50) | DGIdb |
| ENCLOMIPHENE CITRATE | ? unclear | Mechanistic | DGIdb | |
| NLRP3 INHIBITOR 3 [PMID: 33255820] | ↓ inhibits | Mechanistic | DGIdb | |
| RRX-001 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 17 [WO2024240153] | ↓ inhibits | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| ORIDONIN | ↓ inhibits | Mechanistic | DGIdb | |
| NT-0249 | ↓ inhibits | Mechanistic | DGIdb | |
| ALAPROCLATE HYDROCHLORIDE | ? unclear | Mechanistic | 8020.0 nM (IC50) | DGIdb |
| YCT-529 | ↓ inhibits | Mechanistic | DGIdb | |
| GDC-2394 | ~ modulates | Mechanistic | DGIdb | |
| CP-424,174 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL1336269 | ↓ inhibits | Mechanistic | 8010.0 nM (IC50) | ChEMBL |
| CHEMBL1596681 | ↓ inhibits | Mechanistic | 9020.0 nM (IC50) | ChEMBL |
| CHEMBL1447078 | ↓ inhibits | Mechanistic | 53900.0 nM (IC50) | ChEMBL |
| CHEMBL1457403 | ↓ inhibits | Mechanistic | 4790.0 nM (IC50) | ChEMBL |
| CHEMBL1539913 | ↓ inhibits | Mechanistic | 35400.0 nM (IC50) | ChEMBL |
| CHEMBL1366588 | ↓ inhibits | Mechanistic | 2070.0 nM (IC50) | ChEMBL |
| CHEMBL1709001 | ↓ inhibits | Mechanistic | 14900.0 nM (IC50) | ChEMBL |
| CHEMBL1329507 | ↓ inhibits | Mechanistic | 11000.0 nM (IC50) | ChEMBL |
| CHEMBL1507547 | ↓ inhibits | Mechanistic | 76600.0 nM (IC50) | ChEMBL |
| CLOMIPHENE | ↓ inhibits | Mechanistic | 29300.0 nM (IC50) | ChEMBL |
| CHEMBL1339092 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL1574982 | ↓ inhibits | Mechanistic | 3530.0 nM (IC50) | ChEMBL |
| CHEMBL1558285 | ↓ inhibits | Mechanistic | 14300.0 nM (IC50) | ChEMBL |
Showing top 40 of 156 agents ranked by evidence tier.
RARA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AROTINOID ACID | ↑ activates | Mechanistic | DGIdb | |
| COLCHICINE | ? unclear | Mechanistic | DGIdb | |
| TAZAROTENE | ↑ activates | Mechanistic | DGIdb | |
| DIFFERENTIATION INDUCER | ? unclear | Mechanistic | DGIdb | |
| NRX195183 | ↑ activates | Mechanistic | DGIdb | |
| ACITRETIN | ↑ activates | Mechanistic | DGIdb | |
| FENRETINIDE | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ↑ activates | Mechanistic | 0.89 nM (IC50) | DGIdb |
| GERONTOXANTHONE B | ? unclear | Mechanistic | DGIdb | |
| RETINYLRETINOATE | ? unclear | Mechanistic | DGIdb | |
| ABIETIC ACID | ? unclear | Mechanistic | DGIdb | |
| TRIFAROTENE | ↑ activates | Mechanistic | DGIdb | |
| CD666 | ↑ activates | Mechanistic | DGIdb | |
| VITAMIN A | ? unclear | Mechanistic | DGIdb | |
| AGN193836 | ↑ activates | Mechanistic | DGIdb | |
| BMS753 | ↑ activates | Mechanistic | DGIdb | |
| TAMIBAROTENE | ↑ activates | Mechanistic | 78.0 nM (IC50) | DGIdb |
| RECOMBINANT INTERFERON ALFA | ? unclear | Mechanistic | DGIdb | |
| ISOTRETINOIN | ↑ activates | Mechanistic | DGIdb | |
| RO 41-5253 | ↓ inhibits | Mechanistic | DGIdb | |
| LGD-1550 | ? unclear | Mechanistic | DGIdb | |
| AGN193109 | ↓ inhibits | Mechanistic | DGIdb | |
| HEXAMETHYLENE BISACETAMIDE | ? unclear | Mechanistic | DGIdb | |
| PIMARIC ACID | ? unclear | Mechanistic | DGIdb | |
| PALOVAROTENE | ? unclear | Mechanistic | DGIdb | |
| METHYLNITROSOUREA | ? unclear | Mechanistic | DGIdb | |
| DEXAMETHASONE | ? unclear | Mechanistic | DGIdb | |
| LYCOPENE | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| ANTIESTROGEN | ? unclear | Mechanistic | DGIdb | |
| IRX-5183 | ? unclear | Mechanistic | DGIdb | |
| NALOXONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BMS614 | ↓ inhibits | Mechanistic | DGIdb | |
| DIMETHYL SULFOXIDE | ? unclear | Mechanistic | DGIdb | |
| SOY PROTEIN ISOLATE | ? unclear | Mechanistic | DGIdb | |
| TRIBUTYRIN | ? unclear | Mechanistic | DGIdb | |
| YCT-529 | ↓ inhibits | Mechanistic | DGIdb | |
| RECOMBINANT INTERLEUKIN-6 | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC MELATONIN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
RARB
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| KCL-286 | ↑ activates | Mechanistic | DGIdb | |
| ALITRETINOIN | ↑ activates | Mechanistic | 22.0 nM (EC50) | DGIdb |
| TAMIBAROTENE | ↑ activates | Mechanistic | 30.0 nM (Ki) | DGIdb |
| AC261066 | ↑ activates | Mechanistic | DGIdb | |
| AGN193109 | ↓ inhibits | Mechanistic | DGIdb | |
| ACITRETIN | ↑ activates | Mechanistic | DGIdb | |
| TRIFAROTENE | ↑ activates | Mechanistic | DGIdb | |
| TRETINOIN | ↑ activates | Mechanistic | 0.94 nM (IC50) | DGIdb |
| FENRETINIDE | ? unclear | Mechanistic | DGIdb | |
| ADAPALENE | ↑ activates | Mechanistic | 34.0 nM (Ki) | DGIdb |
| TAZAROTENE | ↑ activates | Mechanistic | DGIdb | |
| BMS493 | ↓ inhibits | Mechanistic | DGIdb | |
| RO 40-6055 | ↑ activates | Mechanistic | DGIdb | |
| IRX4310 | ↓ inhibits | Mechanistic | DGIdb | |
| CD666 | ↑ activates | Mechanistic | DGIdb | |
| LGD-1550 | ? unclear | Mechanistic | DGIdb | |
| AROTINOID ACID | ↑ activates | Mechanistic | DGIdb | |
| ISOTRETINOIN | ↑ activates | Mechanistic | DGIdb | |
| PALOVAROTENE | ? unclear | Mechanistic | DGIdb | |
| MOFAROTENE | ~ modulates | Mechanistic | DGIdb | |
| ETRETINATE | ↑ activates | Mechanistic | DGIdb | |
| BMS641 | ↑ activates | Mechanistic | DGIdb | |
| AC55649 | ↑ activates | Mechanistic | DGIdb | |
| RETINOIC ACID AGENT | ? unclear | Mechanistic | DGIdb | |
| YCT-529 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL111217 | ↓ inhibits | Mechanistic | 5681.0 nM (Ki) | ChEMBL |
| CHEMBL130231 | ↓ inhibits | Mechanistic | 5325.0 nM (Ki) | ChEMBL |
| CHEMBL337393 | ↓ inhibits | Mechanistic | 1956.0 nM (Ki) | ChEMBL |
| CHEMBL131826 | ↓ inhibits | Mechanistic | 4623.0 nM (Ki) | ChEMBL |
| CHEMBL335242 | ↓ inhibits | Mechanistic | 6008.0 nM (Ki) | ChEMBL |
| CHEMBL130232 | ↓ inhibits | Mechanistic | 3597.0 nM (Ki) | ChEMBL |
| CHEMBL133915 | ↓ inhibits | Mechanistic | 2112.0 nM (Ki) | ChEMBL |
| CHEMBL422088 | ↓ inhibits | Mechanistic | 3927.0 nM (Ki) | ChEMBL |
| CHEMBL42314 | ↓ inhibits | Mechanistic | 9513.0 nM (Ki) | ChEMBL |
| CHEMBL424269 | ↓ inhibits | Mechanistic | 2270.0 nM (Ki) | ChEMBL |
| CHEMBL132568 | ↓ inhibits | Mechanistic | 1984.0 nM (Ki) | ChEMBL |
| CHEMBL288436 | ↓ inhibits | Mechanistic | 9901.0 nM (Ki) | ChEMBL |
| CHEMBL130374 | ↓ inhibits | Mechanistic | 2112.0 nM (Ki) | ChEMBL |
| CHEMBL424639 | ↓ inhibits | Mechanistic | 2612.0 nM (Ki) | ChEMBL |
| CHEMBL40007 | ↑ activates | Mechanistic | 1100.0 nM (EC50) | ChEMBL |
Showing top 40 of 148 agents ranked by evidence tier.
RARG
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TRETINOIN | ↑ activates | Mechanistic | 0.62 nM (IC50) | DGIdb |
| TAMIBAROTENE | ↑ activates | Mechanistic | DGIdb | |
| ETRETINATE | ↑ activates | Mechanistic | DGIdb | |
| TAZAROTENE | ↑ activates | Mechanistic | DGIdb | |
| ALITRETINOIN | ↑ activates | Mechanistic | 12.0 nM (EC50) | DGIdb |
| PALOVAROTENE | ↑ activates | Mechanistic | DGIdb | |
| ACITRETIN | ↑ activates | Mechanistic | DGIdb | |
| MOFAROTENE | ~ modulates | Mechanistic | DGIdb | |
| AROTINOID ACID | ↑ activates | Mechanistic | DGIdb | |
| RO 40-6055 | ↑ activates | Mechanistic | DGIdb | |
| CD666 | ↑ activates | Mechanistic | DGIdb | |
| AGN193109 | ↓ inhibits | Mechanistic | DGIdb | |
| AHPN | ↑ activates | Mechanistic | DGIdb | |
| ISOTRETINOIN | ↑ activates | Mechanistic | DGIdb | |
| TRIFAROTENE | ↑ activates | Mechanistic | DGIdb | |
| CD2665 | ↓ inhibits | Mechanistic | DGIdb | |
| LGD-1550 | ? unclear | Mechanistic | DGIdb | |
| ADAPALENE | ↑ activates | Mechanistic | 130.0 nM (Ki) | DGIdb |
| IRX4310 | ↓ inhibits | Mechanistic | DGIdb | |
| BMS493 | ↓ inhibits | Mechanistic | DGIdb | |
| MM 11253 | ↓ inhibits | Mechanistic | DGIdb | |
| FENRETINIDE | ? unclear | Mechanistic | DGIdb | |
| YCT-529 | ↓ inhibits | Mechanistic | DGIdb | |
| 3-FLUORO-4-{[(2R)-2-HYDROXY-2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2-NAPHTHALENYL)ACETYL]AMINO}BENZOIC ACID | ↑ activates | Mechanistic | DGIdb | |
| RETINOIC ACID AGENT | ? unclear | Mechanistic | DGIdb | |
| CHEMBL422088 | ↓ inhibits | Mechanistic | 8764.0 nM (Ki) | ChEMBL |
| CHEMBL288436 | ↓ inhibits | Mechanistic | 9901.0 nM (Ki) | ChEMBL |
| CHEMBL40007 | ↑ activates | Mechanistic | 550.0 nM (EC50) | ChEMBL |
| CHEMBL86893 | ↑ activates | Mechanistic | 2700.0 nM (EC50) | ChEMBL |
| CHEMBL89253 | ↑ activates | Mechanistic | 100.0 nM (EC50) | ChEMBL |
| CHEMBL415449 | ↑ activates | Mechanistic | 1100.0 nM (EC50) | ChEMBL |
| CHEMBL285179 | ↑ activates | Mechanistic | 19.0 nM (EC50) | ChEMBL |
| CHEMBL86663 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL39344 | ↑ activates | Mechanistic | 30.0 nM (EC50) | ChEMBL |
| CHEMBL73321 | ↑ activates | Mechanistic | 47.0 nM (EC50) | ChEMBL |
| CHEMBL313742 | ↑ activates | Mechanistic | 1300.0 nM (EC50) | ChEMBL |
| CHEMBL275311 | ↑ activates | Mechanistic | 24.0 nM (EC50) | ChEMBL |
| CHEMBL87147 | ↑ activates | Mechanistic | 1500.0 nM (EC50) | ChEMBL |
| CHEMBL26129 | ↑ activates | Mechanistic | 2000.0 nM (EC50) | ChEMBL |
| CHEMBL284264 | ↑ activates | Mechanistic | 35.0 nM (EC50) | ChEMBL |
Showing top 40 of 140 agents ranked by evidence tier.
SRD5A1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FINASTERIDE | ? unclear | Mechanistic | 911.0 nM (IC50) | DGIdb |
| CHEMBL:CHEMBL29166 | ? unclear | Mechanistic | DGIdb | |
| ABIRATERONE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| DUTASTERIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LEVONORGESTREL | ? unclear | Mechanistic | DGIdb | |
| BEXLOSTERIDE | ? unclear | Mechanistic | 8.0 nM (IC50) | DGIdb |
| CHEMBL99448 | ↓ inhibits | Mechanistic | 5130.0 nM (IC50) | ChEMBL |
| CHEMBL417109 | ↓ inhibits | Mechanistic | 9.0 nM (Ki) | ChEMBL |
| CHEMBL25081 | ↓ inhibits | Mechanistic | 1200.0 nM (Ki) | ChEMBL |
| CHEMBL99615 | ↓ inhibits | Mechanistic | 127.0 nM (IC50) | ChEMBL |
| CHEMBL97266 | ↓ inhibits | Mechanistic | 920.0 nM (Ki) | ChEMBL |
| CHEMBL96006 | ↓ inhibits | Mechanistic | 298.0 nM (IC50) | ChEMBL |
| CHEMBL138580 | ↓ inhibits | Mechanistic | 1600.0 nM (IC50) | ChEMBL |
| CHEMBL439910 | ↓ inhibits | Mechanistic | 79.43 nM (IC50) | ChEMBL |
| CHEMBL278957 | ↓ inhibits | Mechanistic | 34.67 nM (IC50) | ChEMBL |
| CHEMBL277091 | ↓ inhibits | Mechanistic | 562.34 nM (IC50) | ChEMBL |
| CHEMBL16494 | ↓ inhibits | Mechanistic | 60.26 nM (IC50) | ChEMBL |
| CHEMBL279417 | ↓ inhibits | Mechanistic | 32.36 nM (IC50) | ChEMBL |
| CHEMBL15917 | ↓ inhibits | Mechanistic | 32.36 nM (IC50) | ChEMBL |
| CHEMBL16152 | ↓ inhibits | Mechanistic | 151.36 nM (IC50) | ChEMBL |
| CHEMBL16456 | ↓ inhibits | Mechanistic | 173.78 nM (IC50) | ChEMBL |
| CHEMBL439908 | ↓ inhibits | Mechanistic | 89.13 nM (IC50) | ChEMBL |
| CHEMBL278049 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL16248 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL279131 | ↓ inhibits | Mechanistic | 7.943 nM (IC50) | ChEMBL |
| CHEMBL16027 | ↓ inhibits | Mechanistic | 114.82 nM (IC50) | ChEMBL |
| CHEMBL16330 | ↓ inhibits | Mechanistic | 114.82 nM (IC50) | ChEMBL |
| CHEMBL279420 | ↓ inhibits | Mechanistic | 32.36 nM (IC50) | ChEMBL |
| CHEMBL278981 | ↓ inhibits | Mechanistic | 34.67 nM (IC50) | ChEMBL |
| EPRISTERIDE | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL77650 | ↓ inhibits | Mechanistic | 990.0 nM (IC50) | ChEMBL |
| CHEMBL24464 | ↓ inhibits | Mechanistic | 709.0 nM (IC50) | ChEMBL |
| CHEMBL311624 | ↓ inhibits | Mechanistic | 1300.0 nM (IC50) | ChEMBL |
| CHEMBL76373 | ↓ inhibits | Mechanistic | 8400.0 nM (IC50) | ChEMBL |
| CHEMBL2311155 | ↓ inhibits | Mechanistic | 2700.0 nM (IC50) | ChEMBL |
| CHEMBL311013 | ↓ inhibits | Mechanistic | 50300.0 nM (IC50) | ChEMBL |
| CHEMBL76959 | ↓ inhibits | Mechanistic | 490.0 nM (IC50) | ChEMBL |
| CHEMBL312466 | ↓ inhibits | Mechanistic | 620.0 nM (IC50) | ChEMBL |
| CHEMBL283564 | ↓ inhibits | Mechanistic | 981.0 nM (IC50) | ChEMBL |
| CHEMBL77169 | ↓ inhibits | Mechanistic | 820.0 nM (IC50) | ChEMBL |
Showing top 40 of 164 agents ranked by evidence tier.
SREBF1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT NEUROTROPHIC FACTOR | ? unclear | Mechanistic | DGIdb | |
| CALCIFEDIOL ANHYDROUS | ↓ inhibits | Mechanistic | 1176.0 nM (IC50) | ChEMBL |
| CHEMBL4876668 | ↓ inhibits | Mechanistic | 1160.0 nM (IC50) | ChEMBL |
| CHEMBL4851466 | ↓ inhibits | Mechanistic | 722.7 nM (IC50) | ChEMBL |
| CHEMBL4851396 | ↓ inhibits | Mechanistic | 1600.0 nM (IC50) | ChEMBL |
| CHEMBL1824673 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL1824658 | ↓ inhibits | Mechanistic | 5000.0 nM (IC50) | ChEMBL |
| T091317 | ↑ activates | Mechanistic | 20.0 nM (EC50) | ChEMBL |
| CHEMBL5597106 | ↑ activates | Mechanistic | 31000.0 nM (EC50) | ChEMBL |
| CHEMBL5596392 | ↑ activates | Mechanistic | 20000.0 nM (EC50) | ChEMBL |
| CHEMBL5597291 | ↑ activates | Mechanistic | 1500.0 nM (EC50) | ChEMBL |
| CHEMBL5590383 | ↑ activates | Mechanistic | 4300.0 nM (EC50) | ChEMBL |
| CHEMBL5596520 | ↑ activates | Mechanistic | 38000.0 nM (EC50) | ChEMBL |
| CHEMBL5597394 | ↑ activates | Mechanistic | 1300.0 nM (EC50) | ChEMBL |
| CHEMBL5598279 | ↑ activates | Mechanistic | 2800.0 nM (EC50) | ChEMBL |
| CHEMBL5597319 | ↑ activates | Mechanistic | 3000.0 nM (EC50) | ChEMBL |
| CHEMBL5596811 | ↑ activates | Mechanistic | 2900.0 nM (EC50) | ChEMBL |
| CHEMBL5597943 | ↑ activates | Mechanistic | 6900.0 nM (EC50) | ChEMBL |
| CHEMBL5596386 | ↑ activates | Mechanistic | 570.0 nM (EC50) | ChEMBL |
| CHEMBL5596592 | ↑ activates | Mechanistic | 12000.0 nM (EC50) | ChEMBL |
| CHEMBL5596248 | ↑ activates | Mechanistic | 190.0 nM (EC50) | ChEMBL |
| CHEMBL5596939 | ↑ activates | Mechanistic | 1800.0 nM (EC50) | ChEMBL |
| CHEMBL5598331 | ↑ activates | Mechanistic | 1300.0 nM (EC50) | ChEMBL |
| CHEMBL5596815 | ↑ activates | Mechanistic | 310.0 nM (EC50) | ChEMBL |
| CHEMBL5597153 | ↑ activates | Mechanistic | 240.0 nM (EC50) | ChEMBL |
| CHEMBL5597982 | ↑ activates | Mechanistic | 130.0 nM (EC50) | ChEMBL |
| CHEMBL5598250 | ↑ activates | Mechanistic | 770.0 nM (EC50) | ChEMBL |
| CHEMBL5590706 | ↑ activates | Mechanistic | 190.0 nM (EC50) | ChEMBL |
| CHEMBL5596907 | ↑ activates | Mechanistic | 8600.0 nM (EC50) | ChEMBL |
TLR2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TLR AGONIST CADI-05 | ? unclear | Mechanistic | DGIdb | |
| ADALIMUMAB | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb | |
| TOMARALIMAB | ? unclear | Mechanistic | DGIdb | |
| DIAPEP277 | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| VB-201 | ↓ inhibits | Mechanistic | DGIdb | |
| DIPROVOCIM-1 | ↑ activates | Mechanistic | DGIdb | |
| RESVERATROL HEXANOIC ACID | ? unclear | Mechanistic | DGIdb | |
| DEFOSLIMOD | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1836411 | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 13 [PMID: 23098072] | ↑ activates | Mechanistic | DGIdb | |
| PEPTIDOGLYCAN | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL382272 | ↓ inhibits | Mechanistic | 3070.0 nM (IC50) | ChEMBL |
| CHEMBL383597 | ↓ inhibits | Mechanistic | 900.0 nM (IC50) | ChEMBL |
| CHEMBL372577 | ↓ inhibits | Mechanistic | 950.0 nM (IC50) | ChEMBL |
| CHEMBL380585 | ↓ inhibits | Mechanistic | 5200.0 nM (IC50) | ChEMBL |
| CHEMBL190383 | ↓ inhibits | Mechanistic | 1250.0 nM (IC50) | ChEMBL |
| CHEMBL200206 | ↓ inhibits | Mechanistic | 2150.0 nM (IC50) | ChEMBL |
| CHEMBL200140 | ↓ inhibits | Mechanistic | 22000.0 nM (IC50) | ChEMBL |
| CHEMBL200667 | ↓ inhibits | Mechanistic | 6900.0 nM (IC50) | ChEMBL |
| CHEMBL200398 | ↓ inhibits | Mechanistic | 6460.0 nM (IC50) | ChEMBL |
| MYRISTIC ACID | ↓ inhibits | Mechanistic | 5000.0 nM (IC50) | ChEMBL |
| PALMITIC ACID | ↓ inhibits | Mechanistic | 5000.0 nM (IC50) | ChEMBL |
| CHEMBL490908 | ↓ inhibits | Mechanistic | 230.0 nM (IC50) | ChEMBL |
| CHEMBL446794 | ↓ inhibits | Mechanistic | 900.0 nM (IC50) | ChEMBL |
| CHEMBL448621 | ↓ inhibits | Mechanistic | 240.0 nM (IC50) | ChEMBL |
| CHEMBL473383 | ↓ inhibits | Mechanistic | 460.0 nM (IC50) | ChEMBL |
| CHEMBL414311 | ↓ inhibits | Mechanistic | 5000.0 nM (IC50) | ChEMBL |
| CHEMBL1092429 | ↓ inhibits | Mechanistic | 48.0 nM (IC50) | ChEMBL |
| CHEMBL1092428 | ↓ inhibits | Mechanistic | 1200.0 nM (IC50) | ChEMBL |
| CHEMBL1923536 | ↑ activates | Mechanistic | 0.45 nM (EC50) | ChEMBL |
| CHEMBL1923537 | ↑ activates | Mechanistic | 1.0 nM (EC50) | ChEMBL |
| CHEMBL1923538 | ↑ activates | Mechanistic | 0.87 nM (EC50) | ChEMBL |
| CHEMBL1923540 | ↑ activates | Mechanistic | 6.48 nM (EC50) | ChEMBL |
| CHEMBL1923541 | ↑ activates | Mechanistic | 0.56 nM (EC50) | ChEMBL |
| CHEMBL1923542 | ↑ activates | Mechanistic | 1.47 nM (EC50) | ChEMBL |
| CHEMBL1923544 | ↑ activates | Mechanistic | 2.11 nM (EC50) | ChEMBL |
| CHEMBL1923545 | ↑ activates | Mechanistic | 1.55 nM (EC50) | ChEMBL |
| CHEMBL1923546 | ↑ activates | Mechanistic | 3.23 nM (EC50) | ChEMBL |
Showing top 40 of 190 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Acne Vulgaris: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study evaluates the efficacy and safety of a new concentration of the fixed-dose combination EF190 in women with moderate acne vulgaris over six 28-day treatment cycles. Eligible participants will be randomized (2:1) ...
The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent...
This study will compare the effectiveness and safety of topical clascoterone 1% cream and adapalene 0.1% cream in patients with mild-to-moderate acne vulgaris. Acne is a common skin condition that causes blackheads, whiteheads, pimples, and inflammation. A total of 130 eligible participants aged 12-...
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
In Dermatology, assessment of people of color remains underrepresented in RCTs (\<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inf...
The clinical trial aims to test a new drug for acne vulgaris. The trial is performed to answer this question "Is it possible to reduce the number of skin lesions on your face/trunk, after daily applications for 12 consecutive weeks of a new drug?". The trial aims to accurately measure the effects of...
The clinical trial aims to test a new drug for acne vulgaris. The trial is performed to answer this question "Is it possible to reduce the number of skin lesions on your face/trunk, after daily applications for 12 consecutive weeks of a new drug?". The trial aims to accurately measure the effects of...
The clinical trial aims to test the long term safety of a new drug for acne vulgaris. The trial is performed to answer this question "Is it safe to apply the IMP daily for up to 52 weeks?". The trial aims to accurately measure the safety and the effects of the new treatment (N-Acetyl-GED-0507-34-LEV...
Acne vulgaris of adult woman has increased over the past 10 years; it affects currently 20% to 30% of adult women. The physiopathology of adult woman acne is distinguished from the teenager one by essentially 2 factors: * hormonal factor with a peripheral hyperandrogenism coupled with an hypersensib...
This clinical study will compare a radiofrequency (RF) treatment with a standard topical treatment for adults with mild-to-moderate inflammatory facial acne vulgaris. Approximately 60 participants will be randomly assigned to one of two treatment groups. Participants in the RF group will receive thr...
The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.
This randomized, evaluator-blinded, split-face study evaluated whether adjunctive lesion-directed 308-nm excimer light improves inflammatory acne outcomes during oral azithromycin therapy. All participants received oral azithromycin 500 mg three times weekly for 8 weeks. One randomly allocated hemif...
Double blinded, randomized, placebo-controlled trial to determine the safety and efficacy of topical AT-004 therapy in participants with acne vulgaris, including assessment of reduction in the number of acne lesions and IGA. A PK sub-study will be performed in a subset of participants. Participants ...
This study is to evaluate the safety, pharmacokinetics, and treatment effect for topically applied CABTREO lotion in pediatric participants ages 9 to 11 years, 11 months with Acne Vulgaris.
The etiology of acne is heavily dependent on the production of sebum by the sebaceous glands that results in the growth of the bacteria c. acnes. If no sebum is present, there is no nutritional source for the c. acnes, the bacteria die, and acne resolves. An FDA approved acne medication consisting o...
Agents Found By Disease-Level Search
Searched directly from “Acne Vulgaris” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
46 agents shown (approved or with trial evidence) — 43 not found by the gene-target search above.
adalimumab
Adapalene/Benzoyl PeroxideNOT in gene-target list
Benzoyl PeroxideNOT in gene-target list
Isotretinoin 40 mgNOT in gene-target list
salicylic acidNOT in gene-target list
Isotretinoin
DMT210 Topical Gel 5%NOT in gene-target list
GK530GNOT in gene-target list
ACCU-D1NOT in gene-target list
Restylane LidocaineNOT in gene-target list
N-Acetyl-GED-0507-34-Levo 5% gelNOT in gene-target list
Zinc gluconateNOT in gene-target list
Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]NOT in gene-target list
Sonelokimab (M1095)NOT in gene-target list
DPSG 7.5%NOT in gene-target list
AczoneNOT in gene-target list
Epiduo GelNOT in gene-target list
Duac GelNOT in gene-target list
Sebacia MicroparticlesNOT in gene-target list
Isotretinoin capsulesNOT in gene-target list
Tazarotene 0.1% gel plus clindamycin 1% gelNOT in gene-target list
Adapalene 0.1% gel plus clindamycin 1% gelNOT in gene-target list
Adapalene Gel 0.1%NOT in gene-target list
Differin® Gel (Adapalene 0.1%, Galderma)NOT in gene-target list
Vegetarian CollagenNOT in gene-target list
KeratinNOT in gene-target list
CeramidesNOT in gene-target list
AstaxanthinNOT in gene-target list
Winlevi (Clascoterone) cream 1%NOT in gene-target list
Adapalene
JNJ 10229570-AAA 1.2%NOT in gene-target list
JNJ 10229570-AAA 3.6%NOT in gene-target list
Ialuxid gelNOT in gene-target list
ACYCNOT in gene-target list
FMX101NOT in gene-target list
isotretinoin (Roaccutane)NOT in gene-target list
IDP-110NOT in gene-target list
ClindamycinNOT in gene-target list
2,5% lidocaine / 2,5% prilocaine creamNOT in gene-target list
7% lidocaine / 7% tetracaine creamNOT in gene-target list
ISOtretinoin 10 MGNOT in gene-target list
HydroxychloroquineNOT in gene-target list
Optical ClearingNOT in gene-target list
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%NOT in gene-target list
Acanya GelNOT in gene-target list
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% productNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.